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Abstract
Background: Randomized trials of Web-based decision aids for prostate-specific antigen (PSA) testing indicate that these
interventions improve knowledge and reduce decisional conflict. However, we do not know about these tools’ impact on people
who spontaneously use a PSA testing patient decision aid on the internet.
Objective: The objectives of this study were to (1) determine the impact of the Web-based PSA Option Grid patient decision
aid on preference shift, knowledge, and decisional conflict; (2) identify which frequently asked questions (FAQs) are associated
with preference shift; and (3) explore the possible relationships between these outcomes.
Methods: Data were collected between January 1, 2016, and December 30, 2017. Users who accessed the Web-based, interactive
PSA Option Grid were provided with 3 options: have a PSA test, no PSA test, or unsure. Users first declared their initial preference
and then completed 5 knowledge questions and a 4-item (yes or no) validated decisional conflict scale (Sure of myself, Understand
information, Risk-benefit ratio, Encouragement; SURE). Next, users were presented with 10 FAQs and asked to identify their
preference for each question based on the information provided. At the end, users declared their final preference and completed
the same knowledge and decisional conflict questions. Paired sample t tests were employed to compare before and after knowledge
and decisional conflict scores. A multinomial regression analysis was performed to determine which FAQs were associated with
a shift in screening preference.
Results: Of all the people who accessed the PSA Option Grid, 39.8% (186/467) completed the interactive journey and associated
surveys. After excluding 22 female users, we analyzed 164 responses. At completion, users shifted their preference to “not having
the PSA test” (43/164, 26.2%, vs 117/164, 71.3%; P<.001), had higher levels of knowledge (112/164, 68.3%, vs 146/164, 89.0%;
P<.001), and lower decisional conflict (94/164, 57.3%, vs 18/164, 11.0%; P<.001). There were 3 FAQs associated with preference
shift: “What does the test involve?” “If my PSA level is high, what are the chances that I have prostate cancer?” and “What are
the risks?” We did not find any relationship between knowledge, decisional conflict, and preference shift.
Conclusions: Unprompted use of the interactive PSA Option Grid leads to preference shift, increased knowledge, and reduced
decisional conflict, which confirms the ability of these tools to influence decision making, even when used outside clinical
encounters.
(JMIR Cancer 2018;4(2):e11102)   doi:10.2196/11102
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Introduction
Randomized trials of Web-based decision aids for the
prostate-specific antigen (PSA) screening test have indicated
that these tools increase user knowledge, reduce decisional
conflict, and reduce interest in having the test in controlled
contexts, where users are recruited to use the intervention [1,2].
However, what can we say about users who choose to use
Web-based decision aids independent of any study recruitment?
Does spontaneous use of a PSA tool have an effect on users’
knowledge and decisional conflict and shift their screening
preferences?
A recent systematic review of 13 randomized trials assessed the
effectiveness of decision aids for decision making in prostate
cancer testing [3]. Regardless of the mode of delivery (ie,
paper-based, Web-based, or video) the majority of decision aids
improved patient knowledge of the PSA screening test and
mitigated decisional conflict [3]. An example of a Web-based
intervention that induced these positive outcomes is Prosdex,
which also lowered the intention to undergo testing by 18% in
comparison with participants in the control group who did not
receive any decision support intervention [1]. Furthermore, a
randomized trial found an almost 10% reduction in PSA
screening and a 30% increase in preference for “watchful
waiting” for those who used a Web-based decision aid compared
to those who viewed public websites [4]. Web-based PSA tools
that are tailored to individual participants increased knowledge
levels among African American men, improved decision quality,
and decreased levels of decision regret at follow-up [5-7].
A Web-based PSA decision aid—“PSA test: yes or no?” Option
Grid—is a platform for men seeking information on the Web.
It is designed for independent use. Individuals (presumably
men) find this tool, independent of any invitation or promotion.
This tool provides evidence-based information on the risks and
pros and cons of the PSA screening test to help users make a
decision that aligns with their preference [8]. The tool assesses
user knowledge, level of decisional conflict, and preference
before and after viewing the information. A prior study among
82 participants shows that users of the PSA Option Grid tend
to become more risk averse, shifting their preference to “not
having the test” after viewing risk information associated with
the screening test and prostate biopsies [9]. This indicates a
real-world impact on screening preference for users who
spontaneously use this tool [9].
In a recent study, researchers used Google Analytics to track
usage data for users of a Web-based decision aid for early-stage
prostate cancer to determine if the tool was helpful and if users
would recommend it to others. Although this study analyzed
data from an unsolicited sample to determine “real-world”
impact, they did not assess outcomes pre- and post decision aid
use [10]. As far as can be determined, there has been no
assessment of the direct impact of using a Web-based PSA
screening decision aid on specific outcomes like preference
shift, knowledge, or decisional conflict without actively
recruiting or providing incentives to users in a research context.
The aims of this study were to: (1) determine the impact of the
Web-based PSA Option Grid patient decision aids on preference
shift, knowledge, and decisional conflict; (2) identify which
frequently asked questions (FAQs) are associated with
preference shift; and (3) explore the possible relationships
between these outcomes.
Methods
Design
We conducted an analysis of data from a longitudinal sample
derived from the Option Grid website of users who searched
for and used the Web-based “PSA test: yes or no?” Option Grid,
independent of any invitation. We assessed user preferences
regarding PSA screening. We also measured levels of knowledge
and decisional conflict before and after using the intervention.
Ethical approval for this study was received from the Dartmouth
College Committee for the Protection of Human Subjects
(STUDY00030776).
Participants
Data from users of the “PSA test: yes or no?” Option Grid
collected between January 1, 2016, and December 30, 2017,
were eligible for inclusion. Data were excluded if the user exited
the Option Grid website prior to completing the entire interactive
process or if the user self-identified as female.
Intervention
Based on the 2017 Cochrane systematic review definition of a
patient decision aid—“decision aids are intended to provide
information and to promote self-help in the treatment
decision-making process, which enables the patient to more
actively participate in this process, if this is his or her
preference”—we identify Option Grid as a patient decision aid
[11]. Option Grid is available in static (PDF) and interactive
(Option Grid interactive journey) formats. Both the paper-based
and interactive versions of the “PSA test: yes or no?” Option
Grid were freely available on the optiongrid.org website until
March 2018. Users searched for and used the tools independent
of any invitation. The tool was not promoted at any time during
the study period. The interactive version of Option Grid was
intended for independent use, but the information provided
could have been used to facilitate a more collaborative
discussion with a physician.
On the Option Grid website, users could have searched for the
PSA interactive Option Grid using the keyword function or
found it on a list of topics they could have browsed through.
Once on the PSA Option Grid webpage, users had the option
of viewing the PDF version of the PSA Option Grid or starting
the “interactive journey.” The same information is presented in
both versions except the interactive journey presents the
information in a sequential interactive method. If the journey
was selected, users provided their demographic information
such as their age group, gender, ethnicity, and geographic
location. Before proceeding, users identified the strength of
their preference, their level of decisional conflict, and their level
of knowledge. Next, 10 FAQs, always presented in the same
order, provided users with evidence-based information on the
PSA test (ie, described the test and indicated the chances of
having prostate cancer in their lifetime, the significance of
having a normal or high PSA level, survival risk, and the
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advantages and risks associated with the PSA test), and the risks
and side effects associated with prostate biopsies and prostate
cancer treatments. Multimedia Appendix 1 illustrates the
interface that the user encountered for the first FAQ of the tool.
To complete the interactive journey, users identified their final
preference and the strength of that preference and completed
the same SURE survey and knowledge questionnaire post-PSA
Option Grid use.
Outcome Measures
The “self-check” knowledge measure contained 5 items that
require a true or false response (Multimedia Appendix 2). The
questions were developed in relation to some of the information
embedded in the interactive PSA Option Grid. Those questions
helped us determine if the user understood the content and
learned new information during the interactive journey. Users
filled out their responses before and after completing the
journey.
Légaré et al developed a short 4-item decisional conflict measure
known as SURE (Sure of myself; Understand information;
Risk-benefit ratio; Encouragement), in which the user responded
yes or no to each of the 4 questions (Multimedia Appendix 3)
[12]. The 4 items are based on the 16-item decisional conflict
scale and the Ottawa Decision Support Framework. The
reliability and validity of SURE was first assessed with
French-speaking pregnant women considering prenatal screening
for Down syndrome and with over 1000 English-speaking
patients in rural New England who were referred to watch
condition-specific video decision aids [12]. SURE was found
to be a reliable and valid measure to “detect clinically significant
decisional conflict” in both groups [12,13]. Results of a
secondary analysis of a clustered randomized trial supported
the conclusions using a primary care sample: SURE showed
“adequate psychometric properties” [13].
We also collected user preference data before and after reading
the information associated with each FAQ in the interactive
Option Grid (Multimedia Appendix 4).
Data Collection and Analysis
A database stored all responses provided by the user throughout
the entire interactive journey; we only analyzed data from users
of the interactive version. This included their responses to the
knowledge questions, SURE survey, and their preferences
pre-and post-Option Grid use.
The 3 preference options were represented in the dataset as
0=having the PSA test, 1=not having the PSA test, and 2=I am
not sure. The McNemar test was used to determine if users
significantly shifted their preference after completing the
interactive journey in comparison with their initial preference
prior to viewing the information. Chi-square tests were
performed to explore possible relationships between knowledge,
decisional conflict, and preference shift.
We conducted a multinomial regression analysis to determine
which FAQs were associated with preference shift. We created
a dependent variable with 4 categories: 0=“having a PSA test”
shifted to “not having a PSA test,” 1=“not having a PSA test”
shifted to “having a PSA test,” 2=“not having a PSA test”
preference retained, and 3=“having a PSA test” preference
retained (reference category). The FAQs represented nominal
independent variables and were inserted as factors in the model.
Due to the fact that multiple treatment options are being
compared for each FAQ, we decided that FAQs with a P value
of ≤.02 would be considered statistically significant in terms of
shifting user preference [9].
Users received a score from 0 to 5 (a perfect score) on the
“self-check” knowledge questionnaires. This score was recorded
as a continuous variable in the database. The pre- and post
knowledge scores were used in a paired sample t test to
determine whether knowledge significantly increased after
Option Grid use. The dataset also contained the user’s responses
(0=no, 1=yes) to each SURE survey item before and after
completing the interactive Option Grid. A perfect score indicated
that the user was not experiencing clinically significant
decisional conflict. A score of ≤3 meant that the user was
experiencing clinically significant decisional conflict [13]. A
paired sample t test was employed to compare the total pre-and
postdecisional conflict scores.
Results
Participant Sample
A total of 467 users accessed the Option Grid website and began
using the Web-based, interactive PSA decision aid. However,
only 186 users completed the entire interactive journey. Of the
186 completed “journeys” (attrition rate of 60.2%, 281/467),
22 users self-identified as female, leaving a sample of 164 users.
The majority of 281 users who dropped out either did so after
viewing the first FAQ (118/281, 42.0%) or at the midway point
of the journey (66/281, 23.5%). Over half (88/164, 53.7%) of
users indicated that they were between the ages of 45-64 years,
and over 70.1% (115/164) of the sample self-identified as white
or not Hispanic or Latino. The majority (87/164, 53.0%) of the
sample resided in North America. See Table 1 for details.
Preference Shift
Prior to being presented with the FAQs, 73.8% (121/164) users
selected “having the PSA test” as their initial preference. After
completing the interactive journey, 28.7% (47/164) users
indicated that they preferred having the PSA test—a decrease
of 45.1% (74/164). The number of users who preferred “not
having the PSA test” increased from 43 users pre-FAQ to 117
users post-FAQ. Overall, a significant preference shift (P<.001)
to “not having a PSA test” occurred after viewing the
information embedded in the interactive tool. Figure 1 illustrates
the decrease in the number of users who selected “having a PSA
test” for each FAQ.
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Table 1. User characteristics for the Web-based, interactive “prostate-specific antigen test: yes or no?” Option Grid.
n (%)Characteristic
Age in years
5 (3.0)18-24
29 (17.7)25-44
88 (53.7)45-64
42 (25.6)>65
Ethnicity
15 (9.1)Hispanic or Latino
115 (70.1)Not Hispanic or Latino
34 (20.7)Not identified
Race
130 (79.3)White
11 (6.7)Black or African American
12 (7.3)Asian
1 (0.6)Native Hawaiian or other Pacific Islander
5 (3.0)American Indian or Alaska Native
5 (3.0)Other or not identified
Geographic region
87 (53.0)North America
8 (4.9)South America
59 (36.0)Europe
1 (0.6)Africa
5 (3.0)Asia
4 (2.4)Australia
Figure 1. Percentage of users who declared their preference for each FAQ: have a prostate-specific antigen (PSA) test, not having a PSA test, or not
sure.
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There were 3 FAQs associated with a preference shift from
“having the PSA test” to “not having the PSA test,” namely,
FAQ1, “What does the test involve?” (P=.002); FAQ 3, “If my
PSA level is high, what are the chances that I have prostate
cancer?” (P=.01); and FAQ 7, “What are the risks?” (P=.01;
Table 2). The majority of users in the sample selected “having
a PSA test” for FAQ 1, which informed them that the PSA is a
blood test that measures the antigen level in the blood from the
prostate gland; no information was provided for the “not having
a PSA test” option. A slight increase in PSA preference occurred
for FAQ 2, where users were presented with the same risk
information for both options: 15% of men will develop prostate
cancer in their lifetime. Numbers significantly declined for
preference of the PSA test at FAQs 3 and 4. When users were
presented with the fact that 30% of men with a high PSA level
have prostate cancer (FAQ 3), albeit inflammation and infection
also increase levels, they shifted their preference to “not having
the PSA test.” Preference for this option continued with FAQ
4, which stated that 15% of men with a normal PSA have
prostate cancer. More users opted for “not having the test” at
FAQ 5, which stated that only 0.6% of men who do not have a
PSA test die from prostate cancer. FAQ 6 represented an
inflection point because this was the only question that reversed
the trend (albeit not significantly) of preferences shifting to
“having the test.” FAQ 6 indicated that 33% of prostate cancers
are aggressive, and a small number will benefit from early
treatment. FAQ 7 significantly shifted preference. It informed
users that the PSA test cannot identify an aggressive form of
prostate cancer and that more tests (biopsies) would be needed.
The number of users who preferred having the screening test
continued to decline after this question until it hit the lowest
point at the last question when only 31.7% (52/164) of the
sample preferred having the PSA test.
Knowledge
Before viewing the FAQs, 68.3% (112/164) users achieved a
perfect score compared with the 89.0% (146/164) users who
achieved a perfect knowledge score after viewing the FAQs.
The mean post-FAQ knowledge score was 4.88 (SD 0.36)
compared with the pre-FAQ knowledge score of 4.64 (SD 0.56).
Overall, there was a statistically significant knowledge increase
after viewing the Web-based, interactive PSA Option Grid FAQs
(t163=−6.70, P<.001).
Decisional Conflict
Before reviewing the FAQs, 89.0% (146/164) users answered
“no” to at least 1 of the 4 SURE survey items, indicating
decisional conflict. After completing the Option Grid interactive
journey, decisional conflict decreased to 42.7% (70/164) users.
Overall, the decisional conflict score pre-FAQs was 1.49 (SD
1.38) and post-FAQs was 3.24 (SD 1.03). A statistically
significant decisional conflict reduction occurred after viewing
the Web-based, interactive PSA Option Grid (t163=−15.234,
P<.001). The percentages of users who selected yes for each
SURE item are listed in Table 3.
Relationship Between Knowledge, Decisional Conflict,
and Preference
Analyses indicated no association or relationship between
preference shift and increased knowledge levels (P=.45) or
between reduced decisional conflict and preference shift (P=.29).
Furthermore, no relationship was established between increased
knowledge and reduced decisional conflict (P=.85).
JMIR Cancer 2018 | vol. 4 | iss. 2 | e11102 | p.5http://cancer.jmir.org/2018/2/e11102/
(page number not for citation purposes)
Scalia et alJMIR CANCER
XSL•FO
RenderX
Table 2. Frequently asked questions (FAQs) associated with preference shift for the interactive prostate-specific antigen (PSA) Option Grid decision
aid based on the multinomial regression analysis.
P valuec“Not having a PSA” preference re-
tained (n=41), OR (95% CI)
“Not having a PSA” shifted to “hav-
ing a PSA” (n=2), OR (95% CI)
“Having a PSA” shifted to “not hav-
ing a PSA” (n=76), ORb (95% CI)
Variablea
.002eFAQ 1: What does the test involve?
1.001.001.00Not sure
9.7×106 (0.00-0.00)d205 (0.00-0.00)d0.48 (0.07-3.09)Have a PSA test
7.0×1013 (0.00-0.00)d0.00 (0.00-0.00)d5.9×105 (0.00-0.00)dNot have PSA
test
.94FAQ 2: What are my chances of having prostate cancer in my lifetime?
1.001.001.00Not sure
0.27 (0.02-4.09)0.00 (0.00-0.00)d0.40 (0.04-3.73)Have a PSA test
0.03 (0.00-0.00)d3.89 (0.00-0.00)d0.12 (0.00-0.00)d
Not have PSA
test
.01eFAQ 3: If my PSA level is high, what are the chances that I have prostate cancer?
1.001.001.00Not sure
0.07 (0.00-1.81)236 (0.00-0.00)d1.02 (0.08-13.63)Have a PSA test
0.26 (0.01-8.23)0.00 (0.00-0.00)d0.71 (0.04-13.73)Not have PSA
Test
.26FAQ 4: If my PSA level is normal, can I be sure that I don’t have prostate cancer?
1.001.001.00Not sure
0.57 (0.02-14.53)2.81×1010 (0.00-0.00)d0.11 (0.01-1.33)Have a PSA test
1.13 (0.04-30.95)94.79 (0.00-0.00)d0.33 (0.02-4.71)Not have PSA
test
.07FAQ 5: Will getting the PSA test lower my chance of dying from prostate cancer?
1.001.001.00Not sure
114.96 (0.78-169.02)2.06×1011 (0.00-0.00)d13.43 (0.73-246)Have a PSA test
223.42 (1.51-330.33)0.00 (0.00-0.00)d17.69 (0.88-353)Not have PSA
test
.09FAQ 6: What are the advantages?
1.001.001.00Not sure
1.66 (0.05-51.22)0.00 (0.00-0.00)d1.60 (0.09-30.35)Have a PSA test
10.72 (0.31-373.95)0.25 (0.00-0.00)d16.23 (0.70-377)Not have PSA
test
.01eFAQ 7: What are the risks?
1.001.001.00Not sure
0.05 (0.00-2.95)0.00 (0.00-0.00)d0.26 (0.01-11.67)Have a PSA test
0.26 (0.00-17.42)0.00 (0.00-0.00)d0.76 (0.02-39.09)Not have PSA
test
.99FAQ 8: What risks are associated with a prostate biopsy?
1.001.001.00Not sure
0.98 (0.01-167.57)0.00 (0.00-0.00)d2.75 (0.05-154)Have a PSA test
1.37 (0.01-237.35)7.64 (7.64-7.64)d4.33 (0.07-255)Not have PSA
test
.89FAQ 9: What other side effects can I expect from a prostate biopsy?
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P valuec“Not having a PSA” preference re-
tained (n=41), OR (95% CI)
“Not having a PSA” shifted to “hav-
ing a PSA” (n=2), OR (95% CI)
“Having a PSA” shifted to “not hav-
ing a PSA” (n=76), ORb (95% CI)
Variablea
1.001.001.00Not sure
0.43 (0.01-15.63)0.00 (0.00-0.00)d0.25 (0.01-4.33)Have a PSA test
0.53 (0.02-18.50)0.00 (0.00-0.00)d0.24 (0.01-4.27)Not have PSA
test
.61FAQ 10: What are the risks associated with prostate cancer treatment?
1.001.001.00Not sure
0.50 (0.03-7.45)0.00 (0.00-0.00)d0.23 (0.03-1.88)Have a PSA test
0.39 (0.03-5.95)0.00 (0.00-0.00)d0.42 (0.05-3.53)Not have PSA
test
aReference category: “having a PSA test” preference retained.
bOR: odds ratio.
cEstimated P value for the association between FAQs and preference shift.
dThe cell sample size was too small; thus, we could not compute OR or CI.
eSignificantly shifted screening preference.
Table 3. The proportion of users who responded “yes” to each item on the Sure of myself, Understand information, Risk-benefit ratio, Encouragement
(SURE) decisional conflict survey before and after viewing the information embedded in the interactive prostate-specific antigen Option Grid.
Yes, n (%)SURE item
PostPre
110 (67.1)55 (33.5)Do you feel sure about the best choice for you?
156 (95.1)52 (31.7)Do you know the benefits and risks of each option?
136 (82.9)63 (38.4)Are you clear about which benefits and risks matter most to you?
129 (78.7)74 (45.1)Do you have enough support and advice to make a choice?
Discussion
Principal Findings
The Web-based interactive PSA Option Grid decision aid shifted
preference toward not having the screening test, increased user
knowledge, and reduced decisional conflict. In particular, there
were 3 elements of information that induced a shift. First, the
description of the PSA test—a blood test that measures the
antigen level in the blood from the prostate—was associated
with the preference of having the PSA test. Second, FAQ 3
(stating that 30% of men with a high PSA level have prostate
cancer, but that inflammation and infection can also increase
PSA levels) shifted user preferences to declining the screening
test. Lastly, the risks of having the PSA test were presented at
FAQ 7, which represents a significant juncture in the “journey”
in terms of shifting user preference to not having the PSA test.
FAQ 7 stated that it is not possible to know whether a cancer
is aggressive with the PSA test alone; a high PSA level means
that one would need more tests like biopsies, and biopsies carry
risks. No relationships were established between knowledge,
decisional conflict, and preference shift.
The main strength of our study is that we obtained information
from a self-selected sample of participants who freely accessed
the Web-based intervention to better understand whether the
effect of using a Web-based tool is replicated in a naturalistic
setting (ie, outside of a controlled, incentivized research
context). However, we know that a self-selected sample of
individuals who access Web-based health information is likely
to have a higher computer literacy and educational attainment,
which means that we may not have had a representative sample
of the greater population. Increasing the sample size and
randomizing the FAQs would strengthen the study findings.
We recognize that having a more diverse sample may have
influenced our findings. Only 6.7% (11/164) participants of our
sample identified as African American people, and we know
that this patient population is considered to be at high risk for
prostate cancer [14]. Further, we were unable to determine
whether users were health care professionals or actual patients.
Lastly, it is important to note that following data analysis, the
interactive PSA Option Grid decision aid (in the Web-based
format used for this study) was removed from the Web in March
2018 and is no longer available for public use.
A paucity of data exists on the outcomes associated with the
use of Web-based PSA decision aids for individuals
spontaneously searching the internet for information. Our study
shows that even for a self-selected sample, a Web-based tool
increased knowledge and reduced decisional conflict. Our
previous work indicated that FAQs 1, 3, and 8 shifted user
preferences to not having the PSA screening test. In this study,
FAQs 1, 3, and 7 shifted preference in the same direction,
confirming that risk information (FAQs 7 and 8 both discuss
risk) may be the active ingredient in the PSA Option Grid
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responsible for the shift [9]. FAQs 7 and 8 discuss the risk of
the PSA test and the risk of the prostate biopsy, respectively.
Thus, we can infer that men value risk information in their
decision making. Our data are also consistent with previous
studies suggesting that men who used Web-based decision aids
reported higher knowledge and lower decisional conflict and
were less likely to want prostate cancer screening [1,2,15,16].
The preference not to undergo screening aligns with the Agency
for Healthcare Research and Quality’s recommendation, which
indicates that the “benefits of PSA-based screening for prostate
cancer do not outweigh the harms” [17].
Our study showed no relationship between knowledge,
decisional conflict, and preference. This differs from Evans et
al’s randomized trial that showed a link between increased
knowledge and a less favorable attitude toward testing [1].
Although we did not test attitude, we still did not see an
association between increased knowledge and preference shift.
Rubel et al used a Solomon 4-group design to demonstrate that
increased knowledge was related to reduced decisional conflict
for those using a prostate cancer screening decision aid [18].
Based on our data, we can infer that men who spontaneously
used the Option Grid already had high levels of knowledge to
begin with, despite being conflicted about their screening
preference. Further investigation is required to better understand
the potential associations between these outcomes. We did not
collect data on the final screening decision of the user; thus,
more research is needed to understand the actual effect of using
interactive decision aids on the quality of the real-world
decision-making process.
In light of the high attrition rate observed in this study, future
work should focus on creating or modifying Web-based patient
decision aids to reduce the burden on the user. Many men search
the internet for credible health information, but the high attrition
rate in our study indicates that interest or engagement is
impacted by the time it takes to complete the Option Grid
interactive journey. For example, an observational Web-log
analysis showed that the mean total time spent on a Web-based
decision aid is 20 minutes [19]. Evidently, these tools, which
rarely undergo extensive usability testing, can be made easier
to use [20]. Furthermore, research should focus on minimizing
the “digital divide” [21]. Men who use these tools tend to be
white people, highly educated, and reasonably computer literate,
with internet access [21,22]. Men exhibiting these characteristics
have a significant advantage in terms of access to health
information. We need to better understand how to reach men
across socioeconomic strata and how to create Web-based tools
that are suitable to all demographics, health literacy levels, and
computer literacy levels.
Conclusion
The Web-based PSA Option Grid decision aid enabled users to
increase their level of knowledge while reducing decisional
conflict. The risk information embedded in the tool shifted
preference away from having the screening test. Efforts should
be made to increase access to evidence-based information for
men in all socioeconomic categories. This would lead men to
be more informed when communicating with their clinician and
would help them make a decision that aligns with their
preference.
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